Insulin degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes
出版年份 2015 全文链接
标题
Insulin degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes
作者
关键词
-
出版物
PEDIATRIC DIABETES
Volume 16, Issue 3, Pages 164-176
出版商
Wiley
发表日期
2015-02-13
DOI
10.1111/pedi.12263
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance
- (2014) Hanne Haahr et al. CLINICAL PHARMACOKINETICS
- Type 1 Diabetes Through the Life Span: A Position Statement of the American Diabetes Association
- (2014) Jane L. Chiang et al. DIABETES CARE
- Efficacy and safety of insulin degludec given as part of basal-bolus treatment with mealtime insulin aspart in type 1 diabetes: a 26-week randomized, open-label, treat-to-target non-inferiority trial
- (2014) M. J. Davies et al. DIABETES OBESITY & METABOLISM
- Assessment and monitoring of glycemic control in children and adolescents with diabetes
- (2014) Marian J Rewers et al. PEDIATRIC DIABETES
- Insulin degludec's ultra-long pharmacokinetic properties observed in adults are retained in children and adolescents with type 1 diabetes
- (2014) Torben Biester et al. PEDIATRIC DIABETES
- Diabetic ketoacidosis and hyperglycemic hyperosmolar state
- (2014) Joseph I Wolfsdorf et al. PEDIATRIC DIABETES
- The Efficacy and Safety of Insulin Degludec Given in Variable Once-Daily Dosing Intervals Compared With Insulin Glargine and Insulin Degludec Dosed at the Same Time Daily: A 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes
- (2013) L. Meneghini et al. DIABETES CARE
- Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN®Basal-Bolus Type 1): 2-year results of a randomized clinical trial
- (2013) B. W. Bode et al. DIABETIC MEDICINE
- Efficacy and Safety of Insulin Degludec in a Flexible Dosing Regimen vs Insulin Glargine in Patients With Type 1 Diabetes (BEGIN: Flex T1): A 26-Week Randomized, Treat-to-Target Trial With a 26-Week Extension
- (2013) Chantal Mathieu et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society
- (2013) Elizabeth R. Seaquist et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes
- (2012) T. Heise et al. DIABETES OBESITY & METABOLISM
- Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial
- (2012) Alan J Garber et al. LANCET
- Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial
- (2012) Simon Heller et al. LANCET
- Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin
- (2012) Ib Jonassen et al. PHARMACEUTICAL RESEARCH
- Assessment and management of hypoglycemia in children and adolescents with diabetes
- (2009) William Clarke et al. PEDIATRIC DIABETES
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now